Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02347774 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)
A Phase 3 study, sponsored by Sunovion Respiratory Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
NCT02347774: Completed Phase 3 study, sponsored by Sunovion Respiratory Development.
NCT02347774 is a Phase 3 study that has completed, run by Sunovion Respiratory Development. The registered enrollment target is 641 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02347774, a Phase 3 study, has completed, sponsored by Sunovion Respiratory Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
Study Summary
This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
Primary Outcome
All collected Spirometry was performed according to internationally accepted standards. Trough FEV1 at Week 12 was defined as the mean of the values collected at two time points 30 minutes apart at approximately 24 hours (± 1 hour) after the previous morning dose. All collected values were used in this analyses, regardless if the subject remained on randomized treatment or not, and regardless if the values might potentially be affected by other therapies or not Values not collected remained as
Interventions
- DRUG SUN-101 50 mcg BID eFlow (CS) nebulizer
- DRUG SUN-101 25 mcg BID eFlow (CS) nebulizer
- DRUG Placebo eFlow (CS) nebulizer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
What the finished NCT02347774 record still lists
NCT02347774 is an interventional study that assigns participants to a tested intervention. The registered 641 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 3 interventions - of which SUN-101 50 mcg BID eFlow (CS) nebulizer is the first listed.
NCT02347774 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02347774 about?
NCT02347774 is a clinical study titled "Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)". This is a trial of 12 weeks of treatment with nebulized SUN-101 using an Investigational eFlow® Closed System (CS) nebulizer in subjects with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014) guidelines.
What is the current status of trial NCT02347774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2015-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02347774?
The interventions under investigation include: SUN-101 50 mcg BID eFlow (CS) nebulizer (DRUG), SUN-101 25 mcg BID eFlow (CS) nebulizer (DRUG), Placebo eFlow (CS) nebulizer (DRUG).
Who is sponsoring clinical trial NCT02347774?
This trial is sponsored by Sunovion Respiratory Development, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02347774's enrollment target sits among peer trials
641 575th of 2000 higher than 1,425 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06319820 · 641 participants · Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- NCT06625060 · 641 participants · Phase 2
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia